Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer

NCT02977468 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Merck 3475 Pembrolizumab
RADIATION: Intraoperative radiation therapy (IORT)

Sponsor

Eileen Connolly

Collaborators

[object Object]